KTRA Kintara Therapeutics Inc
Price (delayed)
$0.174
Market cap
$9.62M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.07
Enterprise value
$3.27M
Kintara Therapeutics, Inc. operates as a clinical and commercial stage drug development company with a focus on the treatment of cancer. The Company focuses on identifying clinical and commercial-stage compounds
Highlights
Kintara Therapeutics's EPS has soared by 62% YoY and by 32% from the previous quarter
Kintara Therapeutics's equity has soared by 56% YoY
Key stats
What are the main financial stats of KTRA
Market
Valuations
Earnings
Shares outstanding
55.3M
Market cap
$9.62M
Enterprise value
$3.27M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.15
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$9.42M
EBITDA
-$9.37M
Free cash flow
-$7.26M
Per share
Balance sheet
Liquidity
EPS
-$4.07
Free cash flow per share
-$0.16
Book value per share
$0.15
Revenue per share
$0
TBVPS
$0.17
Total assets
$7.45M
Total liabilities
$1.52M
Debt
$0
Equity
$5.92M
Working capital
$5.41M
Debt to equity
0
Current ratio
5.04
Quick ratio
4.74
Net debt/EBITDA
0.68
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-257.3%
Return on equity
-852.5%
Return on invested capital
N/A
Return on capital employed
-154.3%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KTRA stock price
How has the Kintara Therapeutics stock price performed over time
Intraday
4.57%
1 week
-3.44%
1 month
-16.98%
1 year
-95.82%
YTD
2.59%
QTD
-35.58%
Financial performance
How have Kintara Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$9.42M
Net income
-$9.33M
Gross margin
N/A
Net margin
N/A
The net income rose by 44% YoY and by 12% QoQ
Kintara Therapeutics's operating income has increased by 44% YoY and by 11% QoQ
Growth
What is Kintara Therapeutics's growth rate over time
Valuation
What is Kintara Therapeutics stock price valuation
P/E
N/A
P/B
1.15
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Kintara Therapeutics's EPS has soared by 62% YoY and by 32% from the previous quarter
The P/B is 73% lower than the 5-year quarterly average of 4.0
Kintara Therapeutics's equity has soared by 56% YoY
Efficiency
How efficient is Kintara Therapeutics business performance
KTRA's ROA has shrunk by 72% YoY but it is up by 16% QoQ
KTRA's return on equity has surged by 54% since the previous quarter
Dividends
What is KTRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KTRA.
Financial health
How did Kintara Therapeutics financials performed over time
The current ratio has surged by 133% year-on-year
Kintara Therapeutics's total liabilities has decreased by 48% YoY and by 26% from the previous quarter
The debt is 100% smaller than the equity
Kintara Therapeutics's equity has soared by 56% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.